Abstract
The aim of this study was to determine the impact of mean platelet volume (MPV) on the strategy for treatment of atrial fibrillation (AF) with respect to stroke prevention.
MPV was analyzed in 265 patients with AF who were undergoing treatment using rhythm or rate control. The primary endpoint was ischemic stroke or a transient ischemic attack (TIA) event.
Kaplan-Meier analysis revealed a significantly higher stroke rate in the rate control group compared to the rhythm control group. A significantly higher stroke rate was observed in the higher tertile MPV group (≥7.9 fL) compared to the lower tertile MPV group (<7.3 fL). When the MPV cut-off level was set to 7.85 fL using the receiver operating characteristic curve, the sensitivity was 80.0% and the specificity was 70.4% for differentiating between the group with stroke and the group without stroke. In the Cox proportional hazard analysis, after adjusting for sex, treatment strategy for AF, high MPV level, antithrombotic treatment, and high CHADS2 score, higher MPV, rate control strategy for treatment of AF, and high CHADS2 score were found to be independent predictors of stroke risk. In addition, patients with AF who were treated using rate control had high stroke risk with an MPV over 7.85 fL and high CHADS2 score.
The results of this study demonstrate that the MPV and the rate control strategy for treatment of AF were predictive markers for stroke; its predictive power for stroke was independent of female sex and high CHADS2 score in patients with AF.
Keywords: Mean platelet volume, rhythm vs. rate control strategy, Atrial fibrillation, Stroke, CHADS2 score.
Current Pharmaceutical Design
Title:Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume
Volume: 19 Issue: 32
Author(s): Soon-Pyo Hong, Dong-Hyun Choi, Hyun-Wook Kim, Bo-Bae Kim, Joong-Wha Chung, Young-Youp Koh and Kyong-Sig Chang
Affiliation:
Keywords: Mean platelet volume, rhythm vs. rate control strategy, Atrial fibrillation, Stroke, CHADS2 score.
Abstract: The aim of this study was to determine the impact of mean platelet volume (MPV) on the strategy for treatment of atrial fibrillation (AF) with respect to stroke prevention.
MPV was analyzed in 265 patients with AF who were undergoing treatment using rhythm or rate control. The primary endpoint was ischemic stroke or a transient ischemic attack (TIA) event.
Kaplan-Meier analysis revealed a significantly higher stroke rate in the rate control group compared to the rhythm control group. A significantly higher stroke rate was observed in the higher tertile MPV group (≥7.9 fL) compared to the lower tertile MPV group (<7.3 fL). When the MPV cut-off level was set to 7.85 fL using the receiver operating characteristic curve, the sensitivity was 80.0% and the specificity was 70.4% for differentiating between the group with stroke and the group without stroke. In the Cox proportional hazard analysis, after adjusting for sex, treatment strategy for AF, high MPV level, antithrombotic treatment, and high CHADS2 score, higher MPV, rate control strategy for treatment of AF, and high CHADS2 score were found to be independent predictors of stroke risk. In addition, patients with AF who were treated using rate control had high stroke risk with an MPV over 7.85 fL and high CHADS2 score.
The results of this study demonstrate that the MPV and the rate control strategy for treatment of AF were predictive markers for stroke; its predictive power for stroke was independent of female sex and high CHADS2 score in patients with AF.
Export Options
About this article
Cite this article as:
Hong Soon-Pyo, Choi Dong-Hyun, Kim Hyun-Wook, Kim Bo-Bae, Chung Joong-Wha, Koh Young-Youp and Chang Kyong-Sig, Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/13816128113199990075
DOI https://dx.doi.org/10.2174/13816128113199990075 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Natural Products in Drug Discovery - Concepts and Approaches for Tracking Bioactivity
Current Organic Chemistry Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> Investigation
Current Medicinal Chemistry A Patient with COVID-19 Pneumonia Presenting with Plural Effusion: A Case Report
Infectious Disorders - Drug Targets Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Organoselenium Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Severe Preeclampsia
Current Women`s Health Reviews Editorial [Hot Topic: Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurological Diseases (Executive Guest Editor: Dipak K. Das)]
Current Pharmaceutical Design An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Microdialysis in Drug Discovery
Current Drug Discovery Technologies Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets